Skip to content

ESTRELLA IMMUNOPHARMA, INC.

ESLA ESLAW

CIK 0001844417

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$14.74M
−195.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.39
−191.7% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$1.38M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
43.03M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings